Hosted on MSN15h
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...
rarediseaseadvisor1d
Clinical Trial Testing Nanomedicine Drug Candidate for PBC Still Recruiting
The phase 1 trial is testing the safety tolerability, pharmacokinetics, and pharmacodynamics of PVT201 in healthy volunteers and patients.
3 Top AI-Powered Biotech Stocks to Buy in February
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...
Money Talks News on MSN2d
Don't Ignore These Early Signs of a Progressive Liver Condition
A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...
COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.